MetLife Investment Management’s Corcept Therapeutics CORT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $458K | Sell |
5,271
-511
| -9% | -$30.9K | ﹤0.01% | 1955 |
|
|
2026
Q1 | $233K | Sell |
5,782
-288
| -5% | -$10.8K | ﹤0.01% | 2154 |
|
|
2025
Q4 | $211K | Buy |
6,070
+53
| +0.9% | +$4.16K | ﹤0.01% | 2246 |
|
|
2025
Q3 | $500K | Buy |
6,017
+174
| +3% | +$12.6K | ﹤0.01% | 1804 |
|
|
2025
Q2 | $429K | Sell |
5,843
-41,520
| -88% | -$3.01M | ﹤0.01% | 1755 |
|
|
2025
Q1 | $5.41M | Sell |
47,363
-1,481
| -3% | -$90.1K | 0.03% | 569 |
|
|
2024
Q4 | $2.46M | Buy |
48,844
+2,186
| +5% | +$115K | 0.01% | 938 |
|
|
2024
Q3 | $2.16M | Sell |
46,658
-180
| -0.4% | -$6.4K | 0.01% | 977 |
|
|
2024
Q2 | $1.52M | Buy |
46,838
+4,515
| +11% | +$124K | 0.01% | 1112 |
|
|
2024
Q1 | $1.07M | Hold |
42,323
| – | – | 0.01% | 1260 |
|
|
2023
Q4 | $1.37M | Hold |
42,323
| – | – | 0.01% | 1136 |
|
|
2023
Q3 | $1.15M | Hold |
42,323
| – | – | 0.01% | 1161 |
|
|
2023
Q2 | $942K | Sell |
42,323
-4,776
| -10% | -$110K | 0.01% | 1299 |
|
|
2023
Q1 | $1.02M | Hold |
47,099
| – | – | 0.01% | 1216 |
|
|
2022
Q4 | $957K | Hold |
47,099
| – | – | 0.01% | 1235 |
|
|
2022
Q3 | $1.21M | Hold |
47,099
| – | – | 0.01% | 1097 |
|
|
2022
Q2 | $1.12M | Hold |
47,099
| – | – | 0.01% | 1157 |
|
|
2022
Q1 | $1.06M | Buy |
47,099
+13,250
| +39% | +$282K | 0.01% | 1290 |
|
|
2021
Q4 | $670K | Hold |
33,849
| – | – | 0.01% | 1329 |
|
|
2021
Q3 | $666K | Sell |
33,849
-5,535
| -14% | -$116K | 0.01% | 1364 |
|
|
2021
Q2 | $866K | Hold |
39,384
| – | – | 0.01% | 1247 |
|
|
2021
Q1 | $937K | Hold |
39,384
| – | – | 0.01% | 1185 |
|
|
2020
Q4 | $1.03M | Sell |
39,384
-4,062
| -9% | -$85.6K | 0.01% | 1117 |
|
|
2020
Q3 | $756K | Hold |
43,446
| – | – | 0.01% | 1169 |
|
|
2020
Q2 | $731K | Hold |
43,446
| – | – | 0.01% | 1176 |
|
|
2020
Q1 | $517K | Hold |
43,446
| – | – | 0.01% | 1201 |
|
|
2019
Q4 | $526K | Hold |
43,446
| – | – | 0.01% | 1441 |
|
|
2019
Q3 | $614K | Hold |
43,446
| – | – | 0.01% | 1310 |
|
|
2019
Q2 | $484K | Sell |
43,446
-86,892
| -67% | -$968K | 0.01% | 1496 |
|
|
2019
Q1 | $1.53M | Buy |
130,338
+86,892
| +200% | +$1.08M | ﹤0.01% | 1416 |
|
|
2018
Q4 | $580K | Hold |
43,446
| – | – | 0.01% | 1279 |
|
|
2018
Q3 | $609K | Hold |
43,446
| – | – | 0.01% | 1409 |
|
|
2018
Q2 | $683K | Hold |
43,446
| – | – | 0.01% | 1214 |
|
|
2018
Q1 | $715K | Hold |
43,446
| – | – | 0.01% | 1162 |
|
|
2017
Q4 | $785K | Buy |
+43,446
| New | +$787K | 0.01% | 1140 |
|
Other funds holding CORT
ISL
PA
MetLife Investment Management's CORT Position: Q2 2026 in Review
MetLife Investment Management reduced its Corcept Therapeutics (CORT) stake by 8.8% in Q2 2026, selling an estimated $30.9K and leaving 5,271 shares worth $458K. The position accounts for ﹤0.01% of the portfolio, ranked #1955.
MetLife Investment Management first reported a position in CORT in Q4 2017 and has held it in 35 quarters since. The position peaked at $5.41M in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.
- MetLife Investment Management held 5,271 shares of Corcept Therapeutics worth $458K as of Q2 2026.
- MetLife Investment Management sold 511 Corcept Therapeutics shares in Q2 2026, an estimated $30.9K.
- Corcept Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1955 holding.
- MetLife Investment Management first reported a position in Corcept Therapeutics in Q4 2017 and has held it in 35 quarters since.
- MetLife Investment Management's Corcept Therapeutics position peaked at $5.41M in Q1 2025.
- 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.
Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.